AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs), today announced that the findings from their Phase 1 study ...
Almasa Distribution is promoting its latest network and hardware products and services at the Info 2002 Kuwait Fair, including the newly expanded networking line with Acelink/Edimax Technology. The ...
(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Autosomal Dominant Polycystic Kidney Disease pipeline constitutes 13+ key companies continuously ...
AL01211, a novel oral GCS inhibitor, shows favorable safety and robust biomarker reduction in Phase 2 trial in Fabry patients NEWARK, Calif., August 14, 2025--(BUSINESS WIRE)--AceLink Therapeutics, a ...
AceLink is advancing a small-molecule treatment option for Fabry disease that could provide a more convenient alternative to the current enzyme replacement therapy standard. AceLink Therapeutics’ ...
SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data ...
Work at Acelink Therapeutics Inc. has led to the identification of Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 interaction inhibitors reported to be useful for the treatment of cancer, lung, ...
Acelink SM81 is a compact (50x36mm) system-on-module based on the MediaTek Filogic 820 (MT7981A/B) processor with WiFi 6 and Ethernet connectivity designed for IoT applications such as routers, access ...
HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results